Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of hVEGF26-104/RFASE therapeutic VEGF vaccine in advanced solid tumors
NL-OMON20622Phase 1Not yet recruiting
- Sponsor
- VU University Medical Center
- Start
- Apr 2014
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hVEGF26-104 in Nonhematologic neoplasms, sponsored by VU University Medical Center. Primary endpoints: Safety and tolerability of hVEGF26-104/RFASE and Serum VEGF neutralization. Planned start Apr 2014; status: not yet recruiting.
02
Drugs
hVEGF26-104
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON20622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20622.